Thursday, June 11, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 45 of 1,261
  1. US 12290651

    Devices and methods for the treatment of body surface disorders

    Verrica Pharmaceuticals Inc. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  2. US 12290567

    Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates

    ARCTURUS THERAPEUTICS, INC. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  3. US 12291557

    Chimeric TIM4 receptors and uses thereof

    Cero Therapeutics Holdings, Inc. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  4. US 12291560

    Dimerizing agent regulated immunoreceptor complexes

    REGENERON PHARMACEUTICALS, INC. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  5. US 12291556

    Parathyroid hormone variants

    Takeda Pharmaceutical Company Limited · Granted May 6, 2025 · Expires May 1, 2045

    granted
  6. US 12290588

    Peptide having activity of improving skin condition and use thereof

    CAREGEN CO., LTD. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  7. WO 2025090898

    ANTICORPS ANTI-RÉCEPTEUR DE LA TRANSFERRINE ET LEURS UTILISATIONS - RÉFÉRENCES CROISÉES AUX DEMANDES CONNEXES

    BIOGEN MA INC [US] · Granted May 1, 2025 · Expires Apr 26, 2045

    granted
  8. WO 2025090858

    PROCÉDÉS D'IDENTIFICATION DE VARIANTS DE CAPSIDE DE VAA AYANT DES CARACTÉRISTIQUES SOUHAITÉES

    BIOGEN MA INC [US] · Granted May 1, 2025 · Expires Apr 26, 2045

    granted
  9. US 12285435

    Multivesicular liposome formulations of dexamethasone

    Pacira Pharmaceuticals, Inc. · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  10. US 12285417

    Methods for treating chronic obstructive pulmonary disease

    Theravance Biopharma R&D IP, LLC · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  11. US 12285424

    Methods for treating neutropenia

    X4 Pharmaceuticals, Inc. · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  12. US 12285419

    Bupivacaine multivesicular liposome formulations and uses thereof

    Pacira Pharmaceuticals, Inc. · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  13. US 12286406

    Inhibitors of receptor interacting protein kinase I for the treatment of disease

    The Board of Regents of the University of Texas System · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  14. US 12285447

    Methods and compositions for treating ulcerative colitis

    Finch Therapeutics Holdings LLC · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  15. US 12285496

    Gene therapy for haploinsufficiency

    The Regents of the University of California · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  16. US 12286407

    Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases

    The Regents of the University of California · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  17. US 12285460

    Pharmaceutical compositions

    RHYTHM PHARMACEUTICALS, INC. · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  18. US 12285392

    Method for modulating metabolism

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  19. US 12285404

    Prevention of rosacea inflammation

    The Regents of the University of California · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  20. US 12285472

    Self-antigen displaying nanoparticles targeting auto-reactive immune factors and uses thereof

    The Regents of the University of California · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  21. US 12286431

    Crystalline forms of a KRas G12C inhibitor

    Mirati Therapeutics, Inc. · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  22. US 12285397

    Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

    OVID THERAPEUTICS INC. · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  23. US 12285490

    ASH1L degraders and methods of treatment therewith

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  24. US 12286480

    Modulators of ROR1-ROR2 binding

    The Regents of the University of California · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.